Is Femasys Inc. (FEMY) a Buy, Sell, or Hold?
NASDAQ : FEMY
Femasys Inc.
$3.57 USD
-$0.03 (-0.83%)
- Volume
- 10.76K
- Average Volume
- 62.04K
- Market Capitalization
- $10.78M
- P/E Ratio
- -0.56
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $22.20
- Year Low
- $3.39
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.91
| Source | Headline |
|---|---|
|
Femasys Regains Compliance with Nasdaq Listing Requirements
ATLANTA, June 24, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today that it received formal notice from The Nasdaq Stock Market LLC (“Nasdaq”) confirming the Company has regained compliance with Listing Rule 5550(a)(2), the minimum bid price requirement for continued listing and that the matter is now closed. globenewswire.com - 2026-06-24 09:00:00 |
|
Femasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ Catheter
-- New catheter complements FemVue® and supports streamlined in-office fertility evaluation -- -- New catheter complements FemVue® and supports streamlined in-office fertility evaluation -- globenewswire.com - 2026-05-13 09:00:00 |
|
Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update
-- With fertility rates at historic lows, Femasys advances access to early infertility care through FemaSeed® Complete, enabling OB/GYNs to treat patients within their own practices -- -- With fertility rates at historic lows, Femasys advances access to early infertility care through FemaSeed® Complete, enabling OB/GYNs to treat patients within their own practices -- globenewswire.com - 2026-05-08 16:05:00 |
|
Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete
-- Integrated sperm preparation and intratubal insemination drive earlier intervention and streamlined, in-office care within routine OB/GYN practice -- ATLANTA, May 05, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today the first revenue-generating commercial use of its fertility portfolio in the OBGYN setting, led by FemaSeed as a first-line infertility treatment. The procedure was supported by FemSperm®, enabling in-office sperm preparation and advancing the shift of fertility care to women's primary physician, where earlier intervention can improve access and outcomes. globenewswire.com - 2026-05-05 09:00:00 |
|
Financial Analysis: CRISPR Therapeutics (NASDAQ:CRSP) and Femasys (NASDAQ:FEMY)
CRISPR Therapeutics (NASDAQ: CRSP - Get Free Report) and Femasys (NASDAQ: FEMY - Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, earnings and dividends. Earnings and Valuation This table compares CRISPR Therapeutics and defenseworld.net - 2026-04-17 01:29:05 |
